BCDA Aug 2024 2.500 call
| Previous Close | 0.0300 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.50 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.0300 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 16 |
GlobeNewswireBioCardia Announces Reverse Stock Split
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock split will become effective at 12:01 a.m. Eastern
- GuruFocus.com
BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...
Discover how BioCardia Inc navigates clinical advancements and financial efficiencies in the first quarter of 2024.
- GlobeNewswire
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlight
